SCHEMBL16078940

SCHEMBL16078940

CC(C)(C)OC(=O)N1CCCC(NNC(=O)OCc2ccccc2)C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.58
STS P08842 1/20 0.49
HSD11B1 P28845 1/20 0.48
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
GPR119 Q8TDV5 1/20 0.47
KDM1A O60341 1/20 0.47
ACKR3 P25106 1/20 0.46
ITGB3 P05106 1/20 0.46
ITGA2B P08514 1/20 0.46
DPP4 P27487 1/20 0.45
KCNH2 Q12809 1/20 0.45
DPP7 Q9UHL4 1/20 0.45
HTT P42858 1/20 0.45
GABRA5 P31644 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
BCHE P06276 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30165296 0.92 USP30 (0.63) USP30HSD11B1JAK2JAK1DPP4
SCHEMBL3313427 0.92 USP30 (0.63) USP30HSD11B1JAK2JAK1DPP4
SCHEMBL3313424 0.92 USP30 (0.63) USP30HSD11B1JAK2JAK1DPP4
SCHEMBL15669949 0.92 USP30 (0.53) USP30HSD11B1JAK2JAK1ITGB3
SCHEMBL26602429 0.92 USP30 (0.53) USP30HSD11B1JAK2JAK1ITGB3
SCHEMBL21295099 0.88 USP30 (0.59) USP30HSD11B1DPP4KCNH2DPP7
SCHEMBL13434239 0.88 USP30 (0.59) USP30HSD11B1DPP4KCNH2DPP7
SCHEMBL20986825 0.88 USP30 (0.54) USP30HSD11B1GPR119ACKR3ITGB3
SCHEMBL20986823 0.88 USP30 (0.54) USP30HSD11B1GPR119ACKR3ITGB3
SCHEMBL21064049 0.88 USP30 (0.58) USP30HSD11B1DPP4KCNH2DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116710439-B Substituted pyrazolopiperidine carboxylic acids BAYER AG (DE) 2026-05-26 CN disclosed
CN-116829545-B Substituted pyrazolylpiperidine carboxylic acids 拜耳公司 2026-05-15 CN disclosed
EP-4656635-A1 SUBSTITUTED BENZENE COMPOUND Daiichi Sankyo Company, Limited (JP) 2025-12-03 EP disclosed
EP-4642784-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 PTC Therapeutics, Inc. (US) 2025-11-05 EP disclosed
CN-115175681-B Use of sGC activators for the treatment of ophthalmic diseases 拜耳公司 2024-10-25 CN disclosed
CN-118787643-A Substituted pyrazolopiperidine carboxylic acids 拜耳公司 2024-10-18 CN disclosed
CN-118791463-A Substituted pyrazolopiperidine carboxylic acids 拜耳公司 2024-10-18 CN disclosed
WO-2024157953-A1 SUBSTITUTED BENZENE COMPOUND 第一三共株式会社 2024-08-02 WO disclosed
CN-114981257-B Substituted pyrazolopiperidine carboxylic acids 拜耳公司 2024-07-05 CN disclosed
WO-2024145623-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 PTC THERAPEUTICS, INC. (US) 2024-07-04 WO disclosed
WO-2022122917-A1 THE USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES BAYER AKTIENGESELLSCHAFT (DE) 2022-06-16 WO disclosed
WO-2022122910-A1 SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS BAYER AKTIENGESELLSCHAFT (DE) 2022-06-16 WO disclosed
WO-2022122913-A1 SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS BAYER AKTIENGESELLSCHAFT (DE) 2022-06-16 WO disclosed
WO-2022122914-A1 SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS BAYER AKTIENGESELLSCHAFT (DE) 2022-06-16 WO disclosed
WO-2022122917-A1 THE USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES BAYER AKTIENGESELLSCHAFT (DE) 2022-06-16 WO disclosed
EP-4011874-A1 SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS Bayer Aktiengesellschaft (DE) 2022-06-15 EP disclosed
EP-4011873-A1 SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS Bayer Aktiengesellschaft (DE) 2022-06-15 EP disclosed
US-20150376193-A1 PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT JANSSEN PHARMACEUTICA NV (BE) 2015-12-31 US disclosed
US-9156847-B2 Processes and intermediates for preparing a medicament JANSSEN PHARMACEUTICA NV (BE) 2015-10-13 US disclosed
US-20140275126-A1 PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT JANSSEN PHARMACEUTICA NV (BE) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376193-A1 PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT BTK, SYK, JAK2 USP30 1811/4885STS 1147/4885HSD11B1 1429/4885
US-20140275126-A1 PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT BTK, SYK, JAK2 USP30 1811/4885STS 1147/4885HSD11B1 1429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.